Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697903 | 0.84 | TTR (0.35) | TTRALBCYP2A6ALDH1A1MEN1 | |
| SCHEMBL4190058 | 0.80 | TTR (0.33) | TTRALBCYP2A6ALDH1A1MEN1 | |
| SCHEMBL1638135 | 0.80 | GPR35 (0.37) | TTRALBCYP2A6ALDH1A1AR | |
| SCHEMBL4196636 | 0.80 | CYP2A6 (0.38) | TTRALBCYP2A6ALDH1A1GPR35 | |
| SCHEMBL3823646 | 0.80 | ALDH1A1 (0.37) | TTRALBCYP2A6ALDH1A1AR | |
| SCHEMBL14992722 | 0.72 | CYP1A1 (0.34) | HDAC8 | |
| SCHEMBL60145 | 0.71 | TTR (0.50) | TTRALBCYP2A6ALDH1A1MEN1 | |
| SCHEMBL501406 | 0.71 | ALDH1A1 (0.52) | TTRALBCYP2A6ALDH1A1MEN1 | |
| SCHEMBL1004620 | 0.71 | ALDH1A1 (0.52) | TTRALBCYP2A6ALDH1A1MEN1 | |
| SCHEMBL289531 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120707-A1 | Compounds and Method of Treating COVID-19 | PFIZER INC. (US) | 2023-04-20 | — | — | US | claimed |
| CN-108530376-B | Organic small molecule material based on 2, 6-dimethyl-4-cyanophenyl receptor unit and preparation and application thereof | 华南理工大学 | 2021-10-22 | — | — | CN | claimed |
| WO-2021067374-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-08 | — | — | WO | claimed |
| US-20210094935-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-01 | — | — | US | claimed |
| US-10381579-B2 | Stability OLED materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-13 | — | — | US | claimed |
| CN-108530376-A | A kind of organic small molecule material and preparation and application based on 2,6- dimethyl -4- cyanophenyl receptor units | 华南理工大学 | 2018-09-14 | — | — | CN | claimed |
| US-20150249225-A1 | STABILITY OLED MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2015-09-03 | — | — | US | claimed |
| US-9051344-B2 | Stability OLED materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2015-06-09 | — | — | US | claimed |
| CN-103360398-B | Triazolopyrimidine HIV-1 retrovirus inhibitor and its preparation method and application thereof | UNIV SHANDONG | 2015-03-25 | — | — | CN | claimed |
| CN-104016990-A | Imidazopyrazine derivatives as well as preparation method and application thereof | UNIV SHANDONG | 2014-09-03 | — | — | CN | claimed |
| WO-1999050250-A1 | HIV INHIBITING PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| EP-0945443-A1 | HIV inhibiting pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-09-29 | — | — | EP | claimed |
| US-5795905-A | 3-AMINO-5-PHENYL-1,2,4-TRIAZOLES | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-08-18 | — | — | US | claimed |
| EP-0627926-B1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | MERCK & CO INC (US) | 1998-08-05 | — | — | EP | claimed |
| EP-0846108-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1998-06-10 | — | — | EP | claimed |
| EP-0627926-A4 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1-g(b) CONVERTING ENZYME. | MERCK & CO INC (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1996039400-A1 | AMINO-SUBSTITUTED THIADIAZOLES, PYRIMIDINES, TRIAZINES OR TRIAZOLES USEFUL AS CTF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 1996-12-12 | — | — | WO | claimed |
| US-5430128-A | Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1995-07-04 | — | — | US | claimed |
| EP-0627926-A1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Merck & Co., Inc. (a New Jersey corp.) (US) | 1994-12-14 | — | — | EP | claimed |
| WO-1993016710-A1 | PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | MERCK & CO., INC. (US) | 1993-09-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230120707-A1 | Compounds and Method of Treating COVID-19 | ACE2, ACE, SARS1 | TTR 1262/4885ALB 474/4885CYP2A6 1165/4885 |
| US-10381579-B2 | Stability OLED materials and devices | OCIAD2, OCIAD1, OSBP2 | TTR 1062/4885ALB 1380/4885CYP2A6 2453/4885 |
| US-20150249225-A1 | STABILITY OLED MATERIALS AND DEVICES | OCIAD2, OCIAD1, OSBP2 | TTR 1062/4885ALB 1380/4885CYP2A6 2453/4885 |
| US-20210094935-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | TTR 4752/4885ALB 4793/4885CYP2A6 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.